Drugs /

thalidomide

Back to Drugs List

Overview

Generic Name(s):
thalidomide
Trade Name(s):
Kevadon, Contergan, Neurosedyn, Distaval, Sedoval K-17, Thalomid, Talimol, Pantosediv, Synovir, and Softenon
NCI Definition [1]:
A synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties. Thalidomide acts primarily by inhibiting both the production of tumor necrosis factor alpha (TNF-alpha) in stimulated peripheral monocytes and the activities of interleukins and interferons. This agent also inhibits polymorphonuclear chemotaxis and monocyte phagocytosis. In addition, thalidomide inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), thereby inhibiting angiogenesis.

Clinical Trials

View Clinical Trials for thalidomide

Thalidomide has been investigated in 8 clinical trials, of which 8 are open and 0 are closed. Of the trials investigating thalidomide, 1 is phase 1 (1 open), 6 are phase 2 (6 open), and 1 is phase 3 (1 open).

EGFR Exon 19 Deletion, EGFR L858R, and KMT2A Fusion are the most frequent biomarker inclusion criteria for thalidomide clinical trials.

Multiple myeloma, atypical teratoid/rhabdoid tumor, and ependymoma are the most common diseases being investigated in thalidomide clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Thalidomide
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating thalidomide and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
48832, 50-35-1, n-(2,6-dioxo-3-piperidyl)phthalimide, α-n-phthalylglutaramide, n-phthalylglutamic acid imide, α-(n-phthalimido)glutarimide, alpha-phthalimidoglutarimide, 2,6-dioxo-3-phthalimidopiperidine, alpha-(n-phthalimido)glutarimide, (±)-n-(2,6-dioxo-3-piperidyl)phthalimide, thalidomide (substance), (+-)-thalidomide, n-phthalylglutamic acid imide, pro-ban m, n-phthalyl-glutaminsaeure-imid, Neurosedyn, Kevadon, Talimol, Softenon, Sedoval K-17, Pantosediv, Distaval, Contergan, Thalomid, Synovir, 2,6-dioxo-3-phthalimidopiperidine, 3-phthalimidoglutarimide, thalidomide, n-phthaloylglutamimide, 2-(2,6-dioxo-3-piperidinyl)-1h-isoindole-1,3(2h)-dione, (+)-thalidomide, 2-(2,6-dioxopiperidin-3-yl) isoindoline-1,3-dione [source: iupac], alpha-phthalimidoglutarimide, thalidomide, sedalis, k-17, thalidomide [chemical/ingredient], n-phthaloylglutamimide, 2-(2,6-dioxo-3-piperidinyl)-1h-isoindole-1,3(2h)-dione, talidomida, (±)-thalidomide, 3-phthalimidoglutarimide, α-phthalimidoglutarimide, (+-)-n-(2,6-dioxo-3-piperidyl)phthalimide, 2, 6-dioxo-3-phthalimidopiperidine, n-phthalylglutamic acid imide, thal, alpha-n-phthalylglutaramide, celgene brand of thalidomide, phthalimide, n-(2, 6-dioxo-3-piperidyl)-, (+)-, alpha-phthalimidoglutarimide, phthalimide, n-(2, 6-dioxo-3-piperidyl)-, (-)-, .alpha.-phthalimidoglutarimide, thalidomide (product), 66847, (-)-thalidomide, n-(2,6-dioxo-3-piperidyl)phthalimide, 91729, 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)isoindoline, thalidomidum, 1h-isoindole-1,3(2h)-dione, 2-(2,6-dioxo-3-piperidinyl)-
Drug Categories [2]:
Angiogenesis inhibitors
Drug Target(s) [2]:
CRBN
NCIT ID [1]:
C870
SNOMED ID [1]:
C-64085

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.